Study guide
3.1 Concentrations, Dilutions, Alligations & Reconstitution
PEBC Pharmacist Qualifying Examination Part I MCQ
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Canadian Pharmacy Regulatory Framework & Federal Legislation
1.1 Food and Drugs Act, Regulations, and Health Canada Oversight 1.2 Controlled Drugs and Substances Act (CDSA) & Controlled Substances Regulations (CSR) 1.3 NAPRA Drug Scheduling Framework & National Model Standards of Practice
2 Chapter 2: Ethics, Scope of Practice & Safety Culture
2.1 Professional Ethics, Fiduciary Duty & Health Information Privacy 2.2 Expanded Scope of Practice: Minor Ailments Prescribing, Renewals & Injections 2.3 Equity, Diversity, Inclusion, Cultural Safety & Continuous Quality Improvement
3 Chapter 3: Pharmaceutical Calculations & Posology
3.1 Concentrations, Dilutions, Alligations & Reconstitution 3.2 Dosing by Weight/BSA, Days Supply & Pediatric/Geriatric Dose Adjustments 3.3 IV Infusion Rates, Drop Factors, Osmolarity & Creatinine Clearance (Cockcroft-Gault)
4 Chapter 4: Compounding, Dispensing & Product Integrity
4.1 Non-Sterile Compounding & Beyond-Use Dating (NAPRA Standards) 4.2 Sterile Preparations & Hazardous Drug Handling (NAPRA / NIOSH Principles) 4.3 Prescription Verification, Auxiliary Labeling, Cold Chain & Medication Incident Prevention (ISMP Canada) 4.4 Dispensing Operations: Interchangeability, Adjudication, Compliance Packaging, Release & Inventory Control
5 Chapter 5: Clinical Pharmacology & Pharmacokinetics
5.1 Pharmacokinetic Principles: Clearance, Volume of Distribution, Half-life & Steady State 5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions 5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities
6 Chapter 6: Evidence-Based Medicine & Literature Appraisal
6.1 Study Designs, Bias & Levels of Evidence in Clinical Research 6.2 Biostatistics: ARR, RRR, NNT, NNH, Confidence Intervals & P-values 6.3 Applying Canadian Practice Guidelines to Clinical Decision-Making 6.4 Drug Information Practice, Diagnostic Test Accuracy & Pharmacoeconomics
7 Chapter 7: Cardiovascular Pharmacotherapy: Hypertension, Dyslipidemia & CAD
7.1 Hypertension Management (Hypertension Canada Guidelines, Targets & Regimens) 7.2 Dyslipidemia & Atherosclerotic Cardiovascular Disease (CCS Guidelines & Statin Therapy) 7.3 Ischemic Heart Disease & Acute Coronary Syndromes (Antiplatelet & Antianginal Therapy)
8 Chapter 8: Cardiovascular Pharmacotherapy: Heart Failure, Arrhythmias & Anticoagulation
8.1 Heart Failure with Reduced & Preserved Ejection Fraction (GDMT & Monitoring) 8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control 8.3 Venous Thromboembolism & Anticoagulation Therapy (DOACs, Warfarin & Thrombosis Canada)
9 Chapter 9: Endocrine & Metabolic Disorders
9.1 Type 2 Diabetes: Glycemic Targets, Non-Insulin Pharmacotherapy (Diabetes Canada) 9.2 Insulin Regimens, Type 1 Diabetes, Hypoglycemia & Diabetic Emergencies (DKA/HHS) 9.3 Thyroid Disorders & Osteoporosis (Diagnostic Parameters & Therapeutic Management)
10 Chapter 10: Respiratory & Gastrointestinal Disorders
10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers) 10.2 Chronic Obstructive Pulmonary Disease (COPD) & Inhaler Delivery Systems 10.3 Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease & GI Bleeding 10.4 Lower GI & Liver Disorders: Constipation, Diarrhea, IBS, IBD & Cirrhosis
11 Chapter 11: Infectious Diseases & Antimicrobial Stewardship
11.1 Respiratory Tract Infections: Otitis, Sinusitis, Pharyngitis, CAP & HAP 11.2 Urinary Tract, Skin/Soft Tissue & Sexually Transmitted Infections 11.3 Systemic Infections, Clostridioides difficile & Antimicrobial Stewardship Principles 11.4 HIV Prevention & Treatment, Viral Hepatitis, Tuberculosis & Fungal Infections
12 Chapter 12: Central Nervous System & Mental Health
12.1 Major Depressive Disorder & Anxiety Disorders (First-Line Agents & Safety) 12.2 Bipolar Disorder, Schizophrenia & Psychopharmacology Monitoring 12.3 Epilepsy, Seizure Types, Antiseizure Medications & Neuropathic Pain 12.4 Dementia, Parkinson Disease, Migraine, Insomnia & Restless Legs Syndrome
13 Chapter 13: Special Populations, Pain Management & Substance Use
13.1 Acute & Chronic Pain Management: Multimodal Analgesia & Opioid Stewardship 13.2 Substance Use Disorders: Opioid Agonist Therapy, Harm Reduction & Alcohol Withdrawal 13.3 Special Populations: Pharmacotherapy in Pregnancy, Lactation & Geriatrics (Deprescribing / Beers) 13.4 Palliative Care & Pediatric Pharmacotherapy
14 Chapter 14: Renal, Rheumatologic, Hematologic & Oncology Supportive Care
14.1 Chronic Kidney Disease, Acute Kidney Injury & Electrolyte Disorders 14.2 Osteoarthritis, Rheumatoid Arthritis & Gout 14.3 Anemias & Oncology Supportive Care
15 Chapter 15: Minor Ailments, Dermatology and Women's & Men's Health
15.1 Minor Ailments I: Allergic Rhinitis, Colds & Influenza, Eye and Ear Conditions 15.2 Minor Ailments II: Acne, Dermatitis, Psoriasis, Lice, Scabies & Sun Protection 15.3 Women's & Men's Health: Contraception, Emergency Contraception, Menopause, BPH, ED & Overactive Bladder
16 Chapter 16: Immunization & Health Promotion
16.1 Immunization Practice: NACI Recommendations, Administration, Cold Chain & Adverse Events 16.2 Health Promotion: Smoking Cessation, Weight Management, Screening & Social Determinants of Health
17 Chapter 17: Patient Care Process, Communication & Stewardship
17.1 The Patient Care Process: Assessment, Care Planning & Patient Interviewing 17.2 Patient Education, Device Counselling, Health Literacy & Overcoming Barriers 17.3 Interprofessional Collaboration, Pharmacy Workflow, Team Delegation & Drug Shortage Stewardship
3.1 Concentrations, Dilutions, Alligations & Reconstitution
Key Takeaways Explain This Topic AI
Percentage strength expressions must be matched strictly to physical states: % w/v represents grams of solute per 100 mL of solution, % v/v represents millilitres of liquid solute per 100 mL of solution, and % w/w represents grams of solute per 100 g of final preparation.
Ratio strength 1:X represents 1 part of active drug per X parts of preparation (e.g., epinephrine 1:1,000 provides 1 mg/mL or 0.1% w/v for intramuscular anaphylaxis, whereas 1:10,000 provides 0.1 mg/mL or 0.01% w/v for intravenous cardiac resuscitation).
Parts per million (ppm) expresses trace solute levels as parts per 1,000,000 parts (equivalent to 1 mg/L 1\text{ mg/L} 1 mg/L or 1 μ g/mL 1\ \mu\text{g/mL} 1 μ g/mL in aqueous media, where 1 ppm = 0.0001 % w/v 1\text{ ppm} = 0.0001\%\text{ w/v} 1 ppm = 0.0001% w/v ).
Alligation alternate determines the proportional parts of two different ingredient strengths needed to compound an intermediate target strength, while alligation medial calculates the resulting weighted average concentration when mixing known quantities of multiple components.
Dry powder antibiotic reconstitution must account for powder displacement volume via V final = V diluent + V powder V_{\text{final}} = V_{\text{diluent}} + V_{\text{powder}} V final = V diluent + V powder , ensuring correct diluent measurement when altering commercial suspension concentrations for pediatric patients.
Last updated: October 2026
3.1 Concentrations, Dilutions, Alligations & Reconstitution
Pharmaceutical calculations form the foundation of safe pharmacy practice and product compounding in Canada. Accuracy in posology, concentration expression, and volumetric compounding protects patients from subtherapeutic treatment failures and toxic overdoses. In community, hospital, and compounding practice environments, pharmacists must fluidly translate between percentage strengths, ratio concentrations, parts per million, and volumetric dilutions.
Expression of Drug Concentrations in Canadian Pharmacy
Drug concentration defines the quantity of an active pharmaceutical ingredient (API) relative to the total quantity of the pharmaceutical preparation. In Canadian pharmacy practice, concentrations are conventionally categorized into three distinct percentage types based on the physical state of the solute and the solvent:
Expression Definition Standard Dimensional Units Common Clinical & Compounding Applications
Percent Weight-in-Volume (% w/v) Grams of solute in 100 mL 100\text{ mL} 100 mL of solution g / 100 mL \text{g}/100\text{ mL} g /100 mL Oral liquids, IV infusions, topical lotions, ophthalmic solutions
Percent Volume-in-Volume (% v/v) Millilitres of liquid solute in 100 mL 100\text{ mL} 100 mL of solution mL / 100 mL \text{mL}/100\text{ mL} mL /100 mL Hydroalcoholic solutions, rubbing alcohol (e.g., 70 % v/v 70\%\text{ v/v} 70% v/v isopropyl alcohol)
Percent Weight-in-Weight (% w/w) Grams of solute in 100 g 100\text{ g} 100 g of final preparation g / 100 g \text{g}/100\text{ g} g /100 g Semisolid ointments, creams, pastes, bulk powders
Note
Unless specified otherwise in official compendia or prescription orders, a percentage concentration for a solid dissolved in a liquid is assumed to represent % w/v , a liquid dissolved in a liquid represents % v/v , and a solid compounded into a semisolid base represents % w/w .
Ratio Strength
Ratio strength expresses concentration as parts of active drug relative to parts of the total formulation. By international convention:
For solids in liquids: 1 : X = 1 g of solute in X mL of solution 1:X = 1\text{ g of solute in } X\text{ mL of solution} 1 : X = 1 g of solute in X mL of solution .
For liquids in liquids: 1 : X = 1 mL of solute in X mL of solution 1:X = 1\text{ mL of solute in } X\text{ mL of solution} 1 : X = 1 mL of solute in X mL of solution .
For solids in solids: 1 : X = 1 g of solute in X g of preparation 1:X = 1\text{ g of solute in } X\text{ g of preparation} 1 : X = 1 g of solute in X g of preparation .
A critical patient-safety application in Canadian acute care is the posology of epinephrine (adrenaline) , where decimal or ratio misinterpretations can cause fatal cardiac arrhythmias or cerebral hemorrhage:
Epinephrine 1 : 1 , 000 w/v 1:1,000\text{ w/v} 1 : 1 , 000 w/v : 1 g 1 , 000 mL = 1 , 000 mg 1 , 000 mL = 1 mg/mL = 0.1 % w/v \frac{1\text{ g}}{1,000\text{ mL}} = \frac{1,000\text{ mg}}{1,000\text{ mL}} = 1\text{ mg/mL} = 0.1\%\text{ w/v} 1 , 000 mL 1 g = 1 , 000 mL 1 , 000 mg = 1 mg/mL = 0.1% w/v Clinical Indication : Intramuscular injection into the anterolateral thigh for acute anaphylaxis.
Epinephrine 1 : 10 , 000 w/v 1:10,000\text{ w/v} 1 : 10 , 000 w/v : 1 g 10 , 000 mL = 1 , 000 mg 10 , 000 mL = 0.1 mg/mL = 0.01 % w/v \frac{1\text{ g}}{10,000\text{ mL}} = \frac{1,000\text{ mg}}{10,000\text{ mL}} = 0.1\text{ mg/mL} = 0.01\%\text{ w/v} 10 , 000 mL 1 g = 10 , 000 mL 1 , 000 mg = 0.1 mg/mL = 0.01% w/v Clinical Indication : Intravenous administration during Advanced Cardiac Life Support (ACLS) resuscitation protocols.
Parts Per Million (PPM) & Parts Per Billion (PPB)
For extremely dilute solutions, such as municipal water fluoridation, residual solvent limits, and trace heavy metal impurities, concentration is expressed as parts per million (ppm) :
ppm = Parts of Solute 1 , 000 , 000 Parts of Total Preparation \text{ppm} = \frac{\text{Parts of Solute}}{1,000,000\text{ Parts of Total Preparation}} ppm = 1 , 000 , 000 Parts of Total Preparation Parts of Solute
In dilute aqueous systems where the specific gravity approximates 1.0 g/mL 1.0\text{ g/mL} 1.0 g/mL ( 1 L ≈ 1 , 000 , 000 mg 1\text{ L} \approx 1,000,000\text{ mg} 1 L ≈ 1 , 000 , 000 mg ):
1 ppm = 1 mg of solute per 1 L of water = 1 μ g/mL 1\text{ ppm} = 1\text{ mg of solute per } 1\text{ L of water} = 1\ \mu\text{g/mL} 1 ppm = 1 mg of solute per 1 L of water = 1 μ g/mL .
In percentage terms: 1 ppm = 1 1 , 000 , 000 × 100 % = 0.0001 % w/v 1\text{ ppm} = \frac{1}{1,000,000} \times 100\% = 0.0001\%\text{ w/v} 1 ppm = 1 , 000 , 000 1 × 100% = 0.0001% w/v .
For example, if Health Canada specifies that drinking water contains 0.7 ppm 0.7\text{ ppm} 0.7 ppm of fluoride ion, each litre of water contains 0.7 mg 0.7\text{ mg} 0.7 mg of fluoride, which equals 0.00007 % w/v 0.00007\%\text{ w/v} 0.00007% w/v .
Dilution and Concentration Principles: The C 1 V 1 = C 2 V 2 C_1 V_1 = C_2 V_2 C 1 V 1 = C 2 V 2 Relationship
When diluting a concentrated stock solution with an inactive vehicle (such as sterile water for injection or petrolatum) or concentrating a preparation by vehicle evaporation, the absolute mass of the active pharmaceutical ingredient remains constant. This conservation of mass yields the universal inverse proportionality equation:
C 1 V 1 = C 2 V 2 or Q 1 C 1 = Q 2 C 2 C_1 V_1 = C_2 V_2 \quad \text{or} \quad Q_1 C_1 = Q_2 C_2 C 1 V 1 = C 2 V 2 or Q 1 C 1 = Q 2 C 2
Where C 1 C_1 C 1 and C 2 C_2 C 2 represent initial and final concentrations, and V 1 V_1 V 1 and V 2 V_2 V 2 (or Q 1 Q_1 Q 1 and Q 2 Q_2 Q 2 ) represent initial and final volumes or weights.
Important
Both concentration terms ( C 1 C_1 C 1 and C 2 C_2 C 2 ) must share identical dimensional units (e.g., both in %, both in mg/mL \text{mg/mL} mg/mL , or both in ratio format), and both quantity terms ( V 1 V_1 V 1 and V 2 V_2 V 2 ) must share identical volumetric or gravimetric units (e.g., both in mL \text{mL} mL or both in g \text{g} g ).
Step-by-Step Worked Dilution Example
Clinical Scenario : A hospital pharmacist receives a physician order to compound 500 mL 500\text{ mL} 500 mL of a 0.05 % w/v 0.05\%\text{ w/v} 0.05% w/v chlorhexidine gluconate topical wound rinse. The pharmacy stock inventory contains only concentrated 4.0 % w/v 4.0\%\text{ w/v} 4.0% w/v chlorhexidine gluconate surgical scrub.
Identify the Knowns and Unknowns :
- Stock concentration ( C 1 C_1 C 1 ) = 4.0 % w/v 4.0\%\text{ w/v} 4.0% w/v
- Stock volume needed ( V 1 V_1 V 1 ) = ? mL ?\text{ mL} ? mL
- Desired target concentration ( C 2 C_2 C 2 ) = 0.05 % w/v 0.05\%\text{ w/v} 0.05% w/v
- Desired target volume ( V 2 V_2 V 2 ) = 500 mL 500\text{ mL} 500 mL
Set up the Equation : ( 4.0 % ) × V 1 = ( 0.05 % ) × 500 mL (4.0\%) \times V_1 = (0.05\%) \times 500\text{ mL} ( 4.0% ) × V 1 = ( 0.05% ) × 500 mL
Solve for V 1 V_1 V 1 : V 1 = 0.05 × 500 mL 4.0 = 25 4.0 = 6.25 mL V_1 = \frac{0.05 \times 500\text{ mL}}{4.0} = \frac{25}{4.0} = 6.25\text{ mL} V 1 = 4.0 0.05 × 500 mL = 4.0 25 = 6.25 mL
Determine the Required Diluent Volume : V diluent = V final − V 1 = 500 mL − 6.25 mL = 493.75 mL V_{\text{diluent}} = V_{\text{final}} - V_1 = 500\text{ mL} - 6.25\text{ mL} = 493.75\text{ mL} V diluent = V final − V 1 = 500 mL − 6.25 mL = 493.75 mL
Compounding Procedure : Accurately measure 6.25 mL 6.25\text{ mL} 6.25 mL of the 4.0 % 4.0\% 4.0% stock solution using a calibrated syringe, transfer to a volumetric cylinder, and bring to a total volume of 500 mL 500\text{ mL} 500 mL with sterile water for irrigation.
Alligation Methods: Alternate and Medial Compounding Math
When combining two or more preparations of differing strengths to obtain an intermediate strength, simple linear dilution formulas cannot be applied directly if both components contain active ingredient. Pharmacists employ alligation alternate to calculate the relative proportions of ingredients, and alligation medial to determine the resulting strength of a mixture.
Alligation Alternate (Grid Method)
Alligation alternate establishes the relative parts of a higher-strength component and a lower-strength component needed to achieve an intermediate target strength:
Place the desired target strength in the center of the grid.
Place the higher available strength at the top-left and the lower available strength (or pure vehicle at 0 % 0\% 0% ) at the bottom-left.
Subtract diagonally across the grid (always taking the absolute difference):
Parts of Higher Strength = ∣ Desired Strength − Lower Strength ∣ = |\text{Desired Strength} - \text{Lower Strength}| = ∣ Desired Strength − Lower Strength ∣
Parts of Lower Strength = ∣ Higher Strength − Desired Strength ∣ = |\text{Higher Strength} - \text{Desired Strength}| = ∣ Higher Strength − Desired Strength ∣
Sum the parts to obtain the total parts of the final formulation.
Convert the proportional parts to actual weights or volumes. Higher Strength (H) Parts of Higher = |Desired - Lower|
- Desired (D)
- Lower Strength (L) Parts of Lower = |Higher - Desired|
- -----------------------------------------------------------------------
- Total Parts = Sum of Parts
- Step-by-Step Worked Alligation Alternate Example
Clinical Scenario : A dermatologist prescribes 120 g 120\text{ g} 120 g of a 1.5 % w/w 1.5\%\text{ w/w} 1.5% w/w hydrocortisone cream. The pharmacy has in stock 2.5 % w/w 2.5\%\text{ w/w} 2.5% w/w hydrocortisone cream and 0.5 % w/w 0.5\%\text{ w/w} 0.5% w/w hydrocortisone cream. How many grams of each cream must be blended?
Set Up the Alligation Grid :
- Higher strength: 2.5 % 2.5\% 2.5%
- Lower strength: 0.5 % 0.5\% 0.5%
- Desired strength: 1.5 % 1.5\% 1.5%
Diagonal Subtraction :
Parts of 2.5 % 2.5\% 2.5% cream = ∣ 1.5 − 0.5 ∣ = 1.0 part = |1.5 - 0.5| = 1.0\text{ part} = ∣1.5 − 0.5∣ = 1.0 part
Parts of 0.5 % 0.5\% 0.5% cream = ∣ 2.5 − 1.5 ∣ = 1.0 part = |2.5 - 1.5| = 1.0\text{ part} = ∣2.5 − 1.5∣ = 1.0 part
Total parts = 1.0 + 1.0 = 2.0 parts = 1.0 + 1.0 = 2.0\text{ parts} = 1.0 + 1.0 = 2.0 parts
Calculate Component Proportions and Weights : Weight of 2.5 % cream = 1.0 part 2.0 parts × 120 g = 60 g \text{Weight of } 2.5\%\text{ cream} = \frac{1.0\text{ part}}{2.0\text{ parts}} \times 120\text{ g} = 60\text{ g} Weight of 2.5% cream = 2.0 parts 1.0 part × 120 g = 60 g Weight of 0.5 % cream = 1.0 part 2.0 parts × 120 g = 60 g \text{Weight of } 0.5\%\text{ cream} = \frac{1.0\text{ part}}{2.0\text{ parts}} \times 120\text{ g} = 60\text{ g} Weight of 0.5% cream = 2.0 parts 1.0 part × 120 g = 60 g
Proof / Verification :
Drug from 2.5 % 2.5\% 2.5% cream: 60 g × 0.025 = 1.5 g 60\text{ g} \times 0.025 = 1.5\text{ g} 60 g × 0.025 = 1.5 g
Drug from 0.5 % 0.5\% 0.5% cream: 60 g × 0.005 = 0.3 g 60\text{ g} \times 0.005 = 0.3\text{ g} 60 g × 0.005 = 0.3 g
Total active drug: 1.5 g + 0.3 g = 1.8 g 1.5\text{ g} + 0.3\text{ g} = 1.8\text{ g} 1.5 g + 0.3 g = 1.8 g
Final concentration: 1.8 g 120 g × 100 % = 1.5 % w/w \frac{1.8\text{ g}}{120\text{ g}} \times 100\% = 1.5\%\text{ w/w} 120 g 1.8 g × 100% = 1.5% w/w . The calculation is confirmed.
Alligation Medial (Weighted Average)
Alligation medial calculates the final concentration obtained when blending known quantities of preparations with known strengths. It represents a weighted arithmetic mean:
Final Concentration (%) = ∑ ( Quantity i × Concentration i ) ∑ Quantity i \text{Final Concentration (\%)} = \frac{\sum (\text{Quantity}_i \times \text{Concentration}_i)}{\sum \text{Quantity}_i} Final Concentration (%) = ∑ Quantity i ∑ ( Quantity i × Concentration i )
Feature Alligation Alternate Alligation Medial
Primary Objective Find unknown quantities/proportions to hit a target strength Find the resulting strength when mixing known quantities
Known Inputs Initial strengths and desired final strength Specific quantities and strengths of each ingredient
Unknown Output Mass or volume of each ingredient required Final percentage concentration of the blended mixture
- Exam Clue "How many grams of each are needed to compound..." "What is the resulting strength when mixing..."
- Dry Powder Reconstitution and Volume Displacement
Many pharmaceutical anti-infective suspensions (e.g., amoxicillin, amoxicillin/clavulanate, cephalexin, azithromycin) are manufactured as dry powder mixtures because of aqueous instability. When reconstituted with purified water, the dry powder dissolves and occupies physical space, contributing to the total final volume. This is termed the powder volume or displacement volume ( V powder V_{\text{powder}} V powder ):
V final = V diluent + V powder V_{\text{final}} = V_{\text{diluent}} + V_{\text{powder}} V final = V diluent + V powder V powder = V final − V diluent V_{\text{powder}} = V_{\text{final}} - V_{\text{diluent}} V powder = V final − V diluent
Failure to account for powder volume displacement when modifying commercial suspension concentrations leads to severe dosing errors.
Step-by-Step Worked Reconstitution Problem
Clinical Scenario : A community pharmacist receives a prescription for amoxicillin oral suspension for an infant requiring fluid restriction. The physician orders a customized concentration of 500 mg / 5 mL 500\text{ mg}/5\text{ mL} 500 mg /5 mL ( 100 mg/mL 100\text{ mg/mL} 100 mg/mL ) using a standard commercial bottle labeled: Amoxicillin Powder for Oral Suspension 250 mg / 5 mL 250\text{ mg}/5\text{ mL} 250 mg /5 mL , 100 mL 100\text{ mL} 100 mL when reconstituted. To reconstitute, add 68 mL 68\text{ mL} 68 mL of water in two portions and shake vigorously.
Determine the Total Active Drug in the Bottle : Total Drug = 100 mL × 250 mg 5 mL = 5 , 000 mg \text{Total Drug} = 100\text{ mL} \times \frac{250\text{ mg}}{5\text{ mL}} = 5,000\text{ mg} Total Drug = 100 mL × 5 mL 250 mg = 5 , 000 mg
Calculate the Dry Powder Volume ( V powder V_{\text{powder}} V powder ) : V powder = V standard final − V labeled diluent = 100 mL − 68 mL = 32 mL V_{\text{powder}} = V_{\text{standard final}} - V_{\text{labeled diluent}} = 100\text{ mL} - 68\text{ mL} = 32\text{ mL} V powder = V standard final − V labeled diluent = 100 mL − 68 mL = 32 mL
Calculate the Desired Final Volume for the Custom Concentration : Target Final Volume = Total Drug (mg) Target Concentration (mg/mL) = 5 , 000 mg 100 mg/mL = 50 mL \text{Target Final Volume} = \frac{\text{Total Drug (mg)}}{\text{Target Concentration (mg/mL)}} = \frac{5,000\text{ mg}}{100\text{ mg/mL}} = 50\text{ mL} Target Final Volume = Target Concentration (mg/mL) Total Drug (mg) = 100 mg/mL 5 , 000 mg = 50 mL
Calculate the Diluent Volume to Add : V water to add = V target final − V powder = 50 mL − 32 mL = 18 mL V_{\text{water to add}} = V_{\text{target final}} - V_{\text{powder}} = 50\text{ mL} - 32\text{ mL} = 18\text{ mL} V water to add = V target final − V powder = 50 mL − 32 mL = 18 mL
Important
Adding 50 mL 50\text{ mL} 50 mL of water directly would yield a final volume of 82 mL 82\text{ mL} 82 mL ( 50 mL + 32 mL 50\text{ mL} + 32\text{ mL} 50 mL + 32 mL ), producing a dangerously subtherapeutic concentration of 61 mg/mL 61\text{ mg/mL} 61 mg/mL ( 305 mg / 5 mL 305\text{ mg}/5\text{ mL} 305 mg /5 mL ) instead of the intended 100 mg/mL 100\text{ mg/mL} 100 mg/mL .
Compounding Pitfalls & Verification Best Practices
To ensure compounding accuracy and score maximally on calculations sections of entry-to-practice exams, candidates must recognize standard traps:
Unit Discordance : Never mix milligrams and grams, or millilitres and litres, without explicit conversion factors.
Specific Gravity Omission in % w/w to % w/v Conversions : For non-aqueous liquids or dense syrups (e.g., glycerin with specific gravity 1.26 g/mL 1.26\text{ g/mL} 1.26 g/mL ), 100 g 100\text{ g} 100 g does not equal 100 mL 100\text{ mL} 100 mL . Use Volume = Weight Specific Gravity \text{Volume} = \frac{\text{Weight}}{\text{Specific Gravity}} Volume = Specific Gravity Weight .
Non-Additive Volumes : Mixing concentrated alcohol with water causes volume contraction due to intermolecular hydrogen bonding. In compounding 70 % v/v 70\%\text{ v/v} 70% v/v ethanol, pharmacists add water quantum sufficiat (q.s.) to the calibration mark in a volumetric flask rather than measuring separate additive volumes.